CINCOR PHARMA INC (CINC) Stock Overview
USA - NASDAQ:CINC - US17240Y1091 - Common Stock
CINC Key Statistics, Chart & Performance
The current stock price of CINC is 29.06 USD. In the past month the price increased by 1.15%. In the past year, price increased by 2%.
CINC Latest News, Press Relases and Analysis
CINC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.11 | 781.26B | ||
| JNJ | JOHNSON & JOHNSON | 18.34 | 458.55B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.76 | 258.24B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.73 | 252.36B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.65 | 235.32B | ||
| MRK | MERCK & CO. INC. | 11.36 | 218.53B | ||
| PFE | PFIZER INC | 7.3 | 140.77B | ||
| SNY | SANOFI-ADR | 11.74 | 125.85B | ||
| GSK | GSK PLC-SPON ADR | 9.65 | 86.97B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.51 | 89.21B | ||
| ZTS | ZOETIS INC | 23.46 | 64.68B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.04 | 44.25B |
Related stock screener links
About CINC
Company Profile
CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The company is headquartered in Waltham, Massachusetts and currently employs 19 full-time employees. The company went IPO on 2022-01-07. The firm is focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the target of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In addition to hypertension, the Company is developing CIN-107 for the treatment of primary aldosteronism (PA) and exploring its utility in ameliorating complications of chronic kidney disease (CKD). The company also exploring its utility in ameliorating complications of CKD. The company is conducting a Phase II clinical trial, which it refers to as its BrigHtn trial.
Company Info
CINCOR PHARMA INC
230 Third Ave., 6Th Floor
Waltham MASSACHUSETTS US
Employees: 19
Phone: 18445311834.0
CINCOR PHARMA INC / CINC FAQ
Can you describe the business of CINCOR PHARMA INC?
CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The company is headquartered in Waltham, Massachusetts and currently employs 19 full-time employees. The company went IPO on 2022-01-07. The firm is focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the target of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In addition to hypertension, the Company is developing CIN-107 for the treatment of primary aldosteronism (PA) and exploring its utility in ameliorating complications of chronic kidney disease (CKD). The company also exploring its utility in ameliorating complications of CKD. The company is conducting a Phase II clinical trial, which it refers to as its BrigHtn trial.
Can you provide the latest stock price for CINCOR PHARMA INC?
The current stock price of CINC is 29.06 USD. The price decreased by -0.48% in the last trading session.
What is the dividend status of CINCOR PHARMA INC?
CINC does not pay a dividend.
How is the ChartMill rating for CINCOR PHARMA INC?
CINC has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is CINCOR PHARMA INC (CINC) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CINC.
Can you provide the number of employees for CINCOR PHARMA INC?
CINCOR PHARMA INC (CINC) currently has 19 employees.
Who owns CINCOR PHARMA INC?
You can find the ownership structure of CINCOR PHARMA INC (CINC) on the Ownership tab.
CINC Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CINC. When comparing the yearly performance of all stocks, CINC is one of the better performing stocks in the market, outperforming 81.02% of all stocks.
CINC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CINC. While CINC has a great health rating, there are worries on its profitability.
CINC Financial Highlights
Over the last trailing twelve months CINC reported a non-GAAP Earnings per Share(EPS) of -17.28. The EPS decreased by -125.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CINC Forecast & Estimates
12 analysts have analysed CINC and the average price target is 39.78 USD. This implies a price increase of 36.89% is expected in the next year compared to the current price of 29.06.